Literature DB >> 17487427

Interleukin-31 stimulates production of inflammatory mediators from human colonic subepithelial myofibroblasts.

Yuhki Yagi1, Akira Andoh, Atsushi Nishida, Makoto Shioya, Takashi Nishimura, Takayoshi Hashimoto, Tomoyuki Tsujikawa, Yasuharu Saito, Yoshihide Fujiyama.   

Abstract

Interleukin (IL)-31 is mainly produced by CD4+ T cells, in particular T cells skewed toward a Th2 phenotype. Here we report for the first time that IL-31 stimulates secretion of proinflammatory cytokines, chemokines and matrix metalloproteinases (MMPs) from human colonic subepithelial myofibroblasts (SEMFs). The effects of IL-31 were investigated by cDNA microarrays, enzyme-linked immunosorbent assay, and real-time PCR. IL-31 effectively induced chemokines [IL-8, GRO-alpha (growth-related oncogene-alpha), MCP-3 (monocyte chemoattractant protein-3), CXCL3, CCL13 and CCL15], proinflammatory cytokines (IL-6, IL-16 and IL-32) and matrix metalloproteinases (MMP-1, MMP-3, MMP-25 and MMP-7). IL-31 dose-dependently induced secretion of IL-6, IL-8, GRO-alpha, MCP-3, MMP-1 and MMP-3. The effects of IL-31 were comparable to the effects of IL-17A. IL-31 and IL-17A showed additive effects on IL-6, IL-8, GRO-alpha, MCP-3, MMP-1 and MMP-3 secretion. In conclusion, we demonstrated that IL-31 is a potent inducer of proinflammatory mediators in human colonic SEMFs. IL-31 may function as a proinflammatory cytokine derived from Th2 cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17487427

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  17 in total

1.  Proinflammatory and regulatory cytokines and chemokines in infants with uncomplicated and severe Plasmodium falciparum malaria.

Authors:  E Ayimba; J Hegewald; A Y Ségbéna; R G Gantin; C J Lechner; A Agosssou; M Banla; P T Soboslay
Journal:  Clin Exp Immunol       Date:  2011-11       Impact factor: 4.330

Review 2.  IL-31 Inhibition as a Therapeutic Approach for the Management of Chronic Pruritic Dermatoses.

Authors:  Youkyung S Roh; Justin Choi; Nishadh Sutaria; Micah Belzberg; Madan M Kwatra; Shawn G Kwatra
Journal:  Drugs       Date:  2021-04-21       Impact factor: 9.546

3.  Role of stem cell factor and bone marrow-derived fibroblasts in airway remodeling.

Authors:  Vladislav A Dolgachev; Matthew R Ullenbruch; Nicholas W Lukacs; Sem H Phan
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

4.  Correlation of IL-31 gene polymorphisms with susceptibility and clinical recurrence of bladder cancer.

Authors:  Qin Li; Tielong Tang; Peng Zhang; Chenlu Liu; Yan Pu; Yan Zhang; Huizi Song; Yanyun Wang; Yaping Song; Min Su; Bin Zhou; Lin Zhang
Journal:  Fam Cancer       Date:  2018-10       Impact factor: 2.375

Review 5.  Interleukin-31: a novel diagnostic marker of allergic diseases.

Authors:  Anja Rabenhorst; Karin Hartmann
Journal:  Curr Allergy Asthma Rep       Date:  2014-04       Impact factor: 4.806

Review 6.  Structures and biological functions of IL-31 and IL-31 receptors.

Authors:  Qing Zhang; Prabhakar Putheti; Qiang Zhou; Quansheng Liu; Wenda Gao
Journal:  Cytokine Growth Factor Rev       Date:  2008-10-15       Impact factor: 7.638

7.  The association of interleukin-31 polymorphisms with interleukin-31 serum levels and risk of systemic lupus erythematosus.

Authors:  Hua-Tuo Huang; Jian-Ming Chen; Jing Guo; Yan Lan; Ye-Sheng Wei
Journal:  Rheumatol Int       Date:  2016-01-14       Impact factor: 2.631

8.  Irreversible effects of trichloroethylene on the gut microbial community and gut-associated immune responses in autoimmune-prone mice.

Authors:  Sangeeta Khare; Kuppan Gokulan; Katherine Williams; Shasha Bai; Kathleen M Gilbert; Sarah J Blossom
Journal:  J Appl Toxicol       Date:  2018-09-05       Impact factor: 3.446

9.  Dendritic cells activated by IFN-γ/STAT1 express IL-31 receptor and release proinflammatory mediators upon IL-31 treatment.

Authors:  Jutta Horejs-Hoeck; Harald Schwarz; Sebastian Lamprecht; Elisabeth Maier; Stefan Hainzl; Maria Schmittner; Gernot Posselt; Angelika Stoecklinger; Thomas Hawranek; Albert Duschl
Journal:  J Immunol       Date:  2012-04-25       Impact factor: 5.422

10.  Inhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosis.

Authors:  D Q Shih; L Zheng; X Zhang; H Zhang; Y Kanazawa; R Ichikawa; K L Wallace; J Chen; C Pothoulakis; H W Koon; S R Targan
Journal:  Mucosal Immunol       Date:  2014-05-21       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.